GIMOXY 1.2 is an injectable Amoxicillin-Clavulanate antibacterial formulation designed for selected susceptible infections requiring parenteral treatment. The combination pairs established beta-lactam activity with beta-lactamase inhibition, providing broader coverage than Amoxicillin alone against appropriate organisms. Its injectable presentation makes it particularly relevant for hospital, institutional and acute-care practice, positioning it as a strong PCD Pharma Injectable Antibiotic offering for physician-focused and hospital-oriented markets.
It inhibits certain beta-lactamase enzymes that can reduce Amoxicillin effectiveness.
Selected moderate to severe susceptible bacterial infections requiring injectable treatment.
No, antibiotics are ineffective against viral illnesses such as common colds and influenza.
Confirm a history of penicillin or cephalosporin allergy before administration. Use according to the diagnosed infection, local susceptibility patterns and physician-directed dose. Renal function should be considered when clinically appropriate. Monitor for hypersensitivity and antibiotic-associated diarrhea. The complete prescribed course should be followed, and unnecessary antibiotic exposure should be avoided to support antimicrobial stewardship.
Common adverse effects may include diarrhea, nausea, vomiting, abdominal discomfort, headache, rash and injection-site reactions. Hypersensitivity reactions can occur, particularly in individuals with penicillin allergy, and may rarely become serious. Antibiotic-associated diarrhea can occasionally be significant. Patients should be monitored for severe rash, facial swelling, breathing difficulty, persistent diarrhea or other unexpected reactions, especially during parenteral treatment.
GIMOXY 1.2: Amoxicillin is a beta-lactam antibiotic that interferes with bacterial cell-wall synthesis by binding to penicillin-binding proteins. This inhibits the formation of essential peptidoglycan structures, weakens the bacterial cell wall and promotes bacterial destruction. Clavulanate acts as a beta-lactamase inhibitor and protects Amoxicillin from degradation by certain beta-lactamase-producing bacteria, thereby extending antibacterial activity against susceptible organisms.
